Last updated 2026-07-27
TL;DR
A certificate of analysis (CoA) confirms a lab tested a specific compounded batch for identity, potency, and purity, it's not an FDA approval and it doesn't replace a prescription or G6PD screening. For acne, topical dapsone (Aczone 5%/7.5%) is FDA-approved and low-risk. Oral dapsone is a sulfone antibiotic that requires G6PD testing before use because of hemolysis risk.
What is a certificate of analysis for a dapsone product?
A certificate of analysis (CoA) is a lab report tied to one specific batch of a compounded or raw material product. It lists what was tested (identity, potency/assay percentage, purity, sometimes sterility or endotoxin level for injectables) and what the results were against a set specification range. Reputable compounding pharmacies commission these from third-party labs and will show them to a prescriber or, sometimes, the patient on request. For dapsone specifically, a CoA on a compounded topical or oral prep should show the active ingredient assayed at something close to label claim, usually a range like 95-105%, along with results for identification (confirming the substance really is dapsone, not a look-alike compound) and often microbial limits if it's a cream or gel base. If it's an injectable or sterile compound, you'd also expect endotoxin and sterility testing data specific to USP Chapter 797 standards for sterile compounding [1]. What a CoA is not: it is not FDA approval, it is not a guarantee the pharmacy that shipped your order followed good practice on every other batch, and it is not a substitute for a doctor screening you for G6PD deficiency before oral use. Treat it as one piece of evidence, not a seal of total safety. If you're buying FDA-approved topical dapsone (Aczone), the product itself already went through FDA's approval pathway with disclosed manufacturing data, described in the drug's approved labeling [2]. A CoA matters most when you're dealing with a compounded (non-FDA-approved) version, which is common for oral dapsone since there's no FDA-approved oral acne product.
Is topical dapsone (Aczone) the same drug as oral dapsone?
Chemically, yes, both use the sulfone drug dapsone. Clinically, they are almost different animals. Topical dapsone gel (Aczone, 5% and 7.5% concentrations) is FDA-approved specifically for acne vulgaris in patients 9 years and older, applied directly to skin [2]. Oral dapsone is an antibiotic and anti-inflammatory drug approved for dermatitis herpetiformis and for leprosy (Hansen's disease) treatment, and it's used off-label for a handful of inflammatory skin and autoimmune conditions [3]. It is absorbed systemically, meaning it circulates through your blood and affects your whole body, more than skin. That systemic exposure is exactly why oral dapsone carries risks that topical never approaches at meaningful levels: hemolytic anemia, methemoglobinemia, agranulocytosis, and a rare but severe drug reaction called dapsone hypersensitivity syndrome [3][4]. The FDA label for oral dapsone states plainly that patients should be screened for glucose-6-phosphate dehydrogenase (G6PD) deficiency before starting therapy, because G6PD-deficient patients face a much higher risk of hemolysis on this drug [3]. Nobody screens for G6PD before slapping on a spot of acne gel, and that's appropriate. Systemic absorption from topical Aczone is low enough that clinically significant hemolysis in G6PD-deficient patients using the topical form has not been an established problem in the trials that supported its approval [2]. If an article, forum post, or seller blurs these two into one "dapsone for acne" story, that's the single most dangerous mistake a reader can walk away with. Keep them separate in your head: topical for acne, oral for a specific, monitored medical indication.
What does the acne evidence actually show for topical dapsone?
The strongest data on topical dapsone for acne comes from the trials that supported FDA approval of Aczone. Two identical 12-week, randomized, double-blind, vehicle-controlled trials of Aczone 5% gel in roughly 3,000 combined patients with acne vulgaris found statistically significant reductions in inflammatory lesion counts compared to vehicle gel alone, per the FDA-approved prescribing information [2]. A once-daily 7.5% formulation was later approved based on additional 12-week trials showing similar efficacy with a more convenient dosing schedule (once daily instead of twice daily for the original 5% gel) [2]. Across the studied population, adverse effects were mostly local: dryness, redness, and peeling at the application site. Systemic effects tied to G6PD status were not a signal that emerged in these topical trials at meaningful rates, which lines up with the pharmacokinetic data showing minimal systemic absorption through skin [2]. That's a real, FDA-reviewed evidence base, not an off-label guess. It's a reasonable option for acne, particularly for patients who don't tolerate benzoyl peroxide well (dapsone gel doesn't bleach fabric the way benzoyl peroxide does, which is a small but real quality-of-life difference many patients notice). What it isn't: a cure-all. Efficacy in the approval trials was measured as "treatment success" (a global score improvement) in roughly a third of patients versus about a quarter on vehicle, meaningful but not dramatic [2]. If you're expecting clear skin in two weeks, recalibrate.
Why would oral dapsone even come up for skin conditions?
Oral dapsone shows up in dermatology for reasons that have nothing to do with routine acne. Its main approved dermatologic use is dermatitis herpetiformis, the intensely itchy blistering rash linked to celiac disease, where oral dapsone can relieve symptoms within days, often before a gluten-free diet has had time to work [3][5]. Outside its approved indications, dermatologists sometimes prescribe oral dapsone off-label for conditions like bullous pemphigoid, cutaneous vasculitis, or severe nodulocystic acne that hasn't responded to standard oral antibiotics or isotretinoin, though evidence for acne specifically is thinner and more anecdotal than the topical data [4]. This is specialist territory. It requires baseline blood work, G6PD testing, and ongoing monitoring, not a self-directed online order. If you see oral dapsone marketed casually as an acne treatment without any mention of G6PD testing or blood monitoring, that's a red flag, not a deal.
What is G6PD deficiency and why does it matter here?
G6PD deficiency is an inherited enzyme deficiency that leaves red blood cells vulnerable to oxidative damage. Certain drugs, including oral dapsone, sulfa antibiotics, and some antimalarials, can trigger acute hemolysis (red blood cell breakdown) in people who have it . It's one of the most common enzyme deficiencies worldwide, affecting an estimated 400 million people globally, with higher prevalence in people of African, Mediterranean, Middle Eastern, and Southeast Asian descent . The CDC and NIH both describe G6PD deficiency as often asymptomatic until triggered by an oxidative stressor like an infection, certain foods (fava beans), or specific drugs . That's exactly the mechanism at play with oral dapsone: even people with no prior symptoms can have a dangerous hemolytic reaction if they're G6PD-deficient and start oral dapsone without knowing their status. The FDA-approved label for oral dapsone specifically instructs clinicians to test G6PD status before starting the drug and states that patients with G6PD deficiency are at "significantly increased risk" for hemolysis and hemolytic anemia [3]. This is a simple blood test, often available through routine labs, and it's non-negotiable in any responsible oral dapsone prescribing process. If a source, seller, or website is willing to send you oral dapsone without this test being part of the conversation, that's a serious gap in care, not a convenience.
What other risks does oral dapsone carry beyond hemolysis?
Hemolysis isn't the only reason oral dapsone needs monitoring. The FDA label and clinical literature describe several other serious adverse effects tied to systemic dapsone exposure [3][4]: - Methemoglobinemia: dapsone's metabolites can convert hemoglobin to a form that can't carry oxygen properly, causing fatigue, shortness of breath, bluish skin discoloration, and in severe cases, organ stress.
- Agranulocytosis: a sharp drop in white blood cells that impairs infection-fighting ability; this is rare but can be life-threatening and typically shows up in the first few months of therapy.
- Dapsone hypersensitivity syndrome: a delayed, severe reaction (usually 2-6 weeks after starting) involving fever, rash, and organ involvement (commonly liver), described in case literature as carrying a real risk of mortality if unrecognized [4].
- Peripheral neuropathy: motor nerve damage with long-term use, usually reversible after stopping the drug. Because of this list, prescribers who use oral dapsone responsibly order baseline complete blood counts, liver function tests, and G6PD screening, then recheck blood counts periodically (often weekly for the first month, then less frequently) [4]. This is not a drug you start and forget about. If your only interaction with a source of oral dapsone is a payment page and a shipping label, with no bloodwork requested, that's not how legitimate treatment looks.
How do I read potency and purity numbers on a CoA?
Most CoAs report potency as a percentage of label claim, with an acceptable range set by pharmacy or USP standards, commonly 90-110% or a tighter 95-105% depending on the compounding pharmacy's internal specs and the substance involved [1]. A result of 98.7% assay, for example, means the batch tested at 98.7% of the amount of dapsone it was supposed to contain, well within a typical acceptable window. Purity and identity testing usually appear as pass/fail against a reference standard, confirming the substance really is dapsone and isn't contaminated above set thresholds with residual solvents or related compounds. For sterile preparations, look for endotoxin results (reported in EU/mL, endotoxin units per milliliter) and a sterility test result, both governed by USP Chapter 797 for pharmacies compounding sterile products [1]. A few practical checks worth doing when you're handed a CoA: 1. Confirm the batch/lot number on the CoA matches the lot number on your product's label. A CoA for a different batch tells you nothing about what's in your hand. 2. Check the test date isn't wildly old relative to the product's expiration or beyond-use date. 3. Confirm the testing lab is named and, ideally, independently identifiable (an ISO 17025-accredited lab, for instance), more than "in-house, no further detail." 4. If potency is reported, make sure it falls inside a stated spec range rather than being presented as a bare number with no context. None of this replaces the clinical side of the equation. A perfect CoA on an oral dapsone batch tells you the pills are what they say they are; it says nothing about whether you've been screened for G6PD deficiency or whether anyone is watching your blood counts.
Should I ask for a certificate of analysis before ordering dapsone?
For topical Aczone from a standard retail pharmacy, you generally don't need to ask. FDA-approved manufactured drugs go through their own strict quality system under FDA's Current Good Manufacturing Practice regulations, and a CoA isn't something patients typically request for a branded, approved product [2]. For compounded dapsone, whether topical or oral, asking for a CoA is a reasonable and low-effort step. A pharmacy that stands behind its compounding should be able to provide one, or at least confirm testing was done, without treating the request as an inconvenience. If a seller can't or won't produce any documentation about batch testing, that tells you something. But the CoA question is secondary to the bigger gate: was this ever a legitimate prescription in the first place? Dapsone, oral or topical, is a prescription drug in the United States. A route that skips a real clinician evaluation, skips G6PD testing for oral use, and leads with a CoA as its main selling point is answering the wrong question. Provider-reviewed routes, where a licensed prescriber actually evaluates your history before any product ships, solve the more important problem first.
How does Dapsone fit into this?
Dapsone Rx exists as a provider-reviewed resource: the point is getting a licensed clinician's evaluation in the loop before anyone talks about doses, cycles, or compounded products, with fulfillment handled by the pharmacy partner actually doing the compounding and testing, not by Dapsone Rx itself. Dapsone Rx doesn't compound or manufacture anything; it connects the clinical review step to a pharmacy partner that does. If you're past the "is this even appropriate for me" question and into practical logistics, dosing structure and calculation are covered separately: see Dapsone Rx dosage and the Dapsone Rx dosage calculator for how strengths and schedules typically get set. For anyone working with an injectable or reconstituted compounded form under a provider's direction, how to reconstitute Dapsone Rx and Dapsone Rx how to inject walk through the mechanics, and Dapsone Rx injection sites and Dapsone Rx cycle length cover the administration and duration questions that come up next.
What should a legitimate dapsone order actually include?
| Prescription required | Yes | Yes | |
|---|---|---|---|
| G6PD testing | Not routinely required [2] | Required before starting [3] | |
| Baseline bloodwork | Not typically needed | CBC, liver function commonly ordered [4] | |
| Ongoing monitoring | Not routine | Periodic CBC, especially first months [4] | |
| FDA approval status | FDA-approved for acne (ages 9+) [2] | Approved for dermatitis herpetiformis/leprosy; acne use is off-label [3] | |
| CoA relevance | Low (manufactured under GMP) | Higher (often compounded) [1] | If you're being offered oral dapsone for plain acne with no mention of G6PD testing, no bloodwork, and no clinician conversation about the hemolysis or agranulocytosis risk, stop and ask why. That's not a minor omission, it's the core safety step for this specific drug. |
Whether you're getting topical Aczone or a compounded oral formulation, a legitimate order has a few consistent markers. Compare them: | Step | Topical dapsone (Aczone) | Oral dapsone |
Frequently asked questions
What is a certificate of analysis for dapsone?
It's a lab report for one specific manufactured or compounded batch showing test results for identity, potency (often expressed as percent of label claim), and purity, sometimes including sterility and endotoxin data for injectable forms. It confirms what's actually in that batch. It is not FDA approval and doesn't replace a prescription or clinical screening like G6PD testing.
Is topical dapsone (Aczone) safe without G6PD testing?
Yes, in the FDA-approved trials for Aczone 5% and 7.5% gel, systemic absorption through skin was low enough that G6PD-related hemolysis was not an established clinical problem, and G6PD testing isn't a routine requirement before using topical dapsone [2]. That's different from oral dapsone, where testing is required.
Why does oral dapsone require G6PD testing but topical doesn't?
Oral dapsone is absorbed systemically and circulates through the whole body, which can trigger hemolysis in people with G6PD deficiency, an inherited enzyme deficiency affecting an estimated 400 million people worldwide [6]. Topical dapsone has minimal systemic absorption through skin, so this risk hasn't shown up as a meaningful problem in its approval trials [2].
Can oral dapsone be used for acne?
It's used off-label for severe, treatment-resistant acne in some dermatology settings, but there's no FDA-approved oral dapsone acne product, and evidence for that use is thinner than for topical Aczone. It requires G6PD testing and blood monitoring given risks like hemolysis and agranulocytosis [3][4], so it's not a casual or self-directed option.
What does a passing potency result on a CoA look like?
Typically a percentage of label claim within a set specification range, commonly somewhere around 95-105% depending on the pharmacy's standards, though ranges vary by substance and compounding guideline [1]. A result like 98.7% assay means the tested batch contained about 98.7% of the labeled amount of active dapsone.
What is dapsone hypersensitivity syndrome?
It's a rare, severe, delayed drug reaction to oral dapsone, usually appearing two to six weeks after starting therapy, involving fever, rash, and organ involvement, most often the liver. Case literature describes real risk of mortality if it's not recognized and the drug isn't stopped promptly [4]. It doesn't occur with topical use at meaningful rates.
Does a good certificate of analysis mean a compounded dapsone product is safe to use?
No. A CoA tells you the tested batch matched its identity and potency specs, which matters, but it says nothing about whether the drug is right for you, whether you've been screened for G6PD deficiency (for oral use), or whether a licensed prescriber actually evaluated you first. All three pieces matter together.
How common is G6PD deficiency?
It's one of the most common enzyme deficiencies in the world, estimated to affect around 400 million people globally, with higher prevalence in people of African, Mediterranean, Middle Eastern, and Southeast Asian descent [6]. Many people don't know they have it until an oxidative trigger like a drug or infection causes symptoms.
What symptoms suggest a hemolytic reaction to dapsone?
Fatigue, unusual paleness, dark urine, jaundice (yellowing skin or eyes), rapid heartbeat, or shortness of breath can all signal hemolysis. Anyone on oral dapsone who develops these symptoms should contact their prescriber promptly; this is exactly why baseline G6PD testing and periodic blood counts are standard parts of monitoring on this drug [3][4].
Is dapsone gel the same strength as oral dapsone tablets?
No, they're different delivery forms of the same drug entirely. Aczone gel comes in 5% and 7.5% topical concentrations applied to skin [2], while oral tablets are dosed in milligrams (commonly ranging from 25mg up to 100mg or more depending on indication) [3] and absorbed systemically. They are not interchangeable and carry very different risk profiles.
Where can I check a compounding pharmacy's testing standards?
Sterile compounding in the U.S. is governed by USP General Chapter 797 standards, which set requirements for testing, environment, and documentation [1]. Ask any compounding pharmacy whether they compound under USP 797 standards and whether they can provide a certificate of analysis tied to your specific batch's lot number.
What should I do before starting oral dapsone for a skin condition?
Get a G6PD blood test, baseline complete blood count, and liver function testing done first, and make sure a licensed prescriber is reviewing your full medical history, more than filling an order. The FDA label for oral dapsone specifically calls for G6PD screening before starting therapy because of hemolysis risk [3].
Sources
- USP General Chapter <797> Pharmaceutical Compounding - Sterile Preparations: Sterile compounded preparations, including endotoxin and sterility testing, are governed by USP Chapter 797 standards
- StatPearls (NIH Bookshelf), Dapsone: Oral dapsone carries risks of methemoglobinemia, agranulocytosis, dapsone hypersensitivity syndrome, and peripheral neuropathy requiring monitoring
- American Academy of Dermatology / NIH literature on dermatitis herpetiformis treatment: Oral dapsone is used to treat dermatitis herpetiformis and can relieve symptoms within days
- CDC, Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: G6PD deficiency affects an estimated 400 million people worldwide and increases risk of drug-triggered hemolysis
- NIH MedlinePlus Genetics, G6PD deficiency: G6PD deficiency is often asymptomatic until triggered by an oxidative stressor such as certain drugs or foods